Fig. 5: Therapeutic ferroptosis inhibition attenuates hepatocyte damage and steatosis in CDAHFD. | Cell Death & Differentiation

Fig. 5: Therapeutic ferroptosis inhibition attenuates hepatocyte damage and steatosis in CDAHFD.

From: Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease

Fig. 5

A Experimental design of UAMC-3203 (12.35 mg/kg bodyweight) or 0.9% NaCl (vehicle) via subcutaneous osmotic minipumps (n = 12 or 16) in animals fed CDAHFD or SD for 4 weeks. B Hepatic MDA. C Serum ALT, AST. D H&E and Masson’s trichrome. Magnification 100×, scale bar 200 µm. E Liver-on-bodyweight ratio. F Quantification of liver area enveloped by macrovesicular steatosis. G Scoring of steatosis, ballooning, lobular inflammation, NAFLD activity score and fibrosis. Mean ± standard deviation. Data from two independent experiments combined. *p < 0.05; **p < 0.01; ***p < 0.001; #p < 0.05 for factor diet. Two-way ANOVA with post-hoc test. Kruskal–Wallis with post-hoc testing for ordinal histologic scoring.

Back to article page